Blog
A new study, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, integrates patient funding programs for pharmacist teams to dramatically improve access to pharmaceutical company funding for uninsured and vulnerable cancer patients.
With the breakthrough of medical technology, various new therapies, precision medicine and medical materials have been introduced, and people have more choices, but they also face a great financial burden. We have long supported the Smart Patient Leadership Academy, which aims to cultivate patient leaders, and provides corporate volunteers, strategic consultants, resource matching and other services. With such support, the Smart Patient Leadership Academy invited experts from all walks of life to share the topic of “The Feasibility of Synergizing Health Insurance with Commercial Insurance” on 8/7, during which they discussed the current situation of health insurance and commercial insurance in Taiwan, and analyzed the current plans of other countries as a reference for future policies.
According to recent research published by JAMA Network Open, lung cancer patients who participated in the trial saw significant improvements in health-related quality of life (HRQOL) in symptom monitoring through active patient reporting systems (PROs) versus patients who received standard of care and were actively questioned by medical personnel. However, there was no significant difference between patient-reported and physician-active interventions, and no statistically significant difference was shown in overall survival. This study can extend the results to provide patients with effective patient support management for long-term symptoms without increasing the workload of healthcare professionals.
In the emerging biopharmaceutical field, the role of the Patient Support Program (PSP) is becoming increasingly important. With the improvement of medical technology and data analysis capabilities, PSPs are gradually moving away from traditional adherence management to outcome-oriented comprehensive support services with the goal of aligning the patient’s treatment context with the clinical design effect. This is also constantly changing the current situation and innovation of patient support services, driving pharmaceutical companies to shift from traditional product-oriented to service-oriented.
